pioglitazone has been researched along with Autoimmune Disease in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we investigated the anti-inflammatory effects of PPAR-γ agonist, pioglitazone, on murine model of endogenous uveitis." | 7.79 | Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis. ( Goto, H; Hattori, T; Kezuka, T; Matsuda, R; Nakagawa, H; Okunuki, Y; Tajima, K; Ueda, S; Usui, Y, 2013) |
| " In the present study, we investigated the anti-inflammatory effects of PPAR-γ agonist, pioglitazone, on murine model of endogenous uveitis." | 3.79 | Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis. ( Goto, H; Hattori, T; Kezuka, T; Matsuda, R; Nakagawa, H; Okunuki, Y; Tajima, K; Ueda, S; Usui, Y, 2013) |
| "As rosiglitazone has recently been linked to a higher risk of heart failure, stroke, and all-cause mortality in old patients, it has been interrupted from the European market." | 2.50 | Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines. ( Antonelli, A; Di Domenicantonio, A; Fallahi, P; Ferrari, SM; Ferri, C; Manfredi, A, 2014) |
| " Then the rats were divided into 3 groups of 9 rats: PPAR-gamma ligand 15-deoxy-(12,14)-PGJ(2) (15d-PGJ(2)) group (15d-PGJ(2) was injected intraperitoneally at the dosage of 200 microg." | 1.32 | [Peroxisome proliferation-activated receptor-gamma ligands ameliorate autoimmune myocarditis associated with inhibition of T cell immunity]. ( Kishimoto, C; Liu, Y; Liu, ZQ; Yuan, ZY; Zhang, JJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Fauber, BP | 1 |
| Gobbi, A | 1 |
| Robarge, K | 1 |
| Zhou, A | 1 |
| Barnard, A | 1 |
| Cao, J | 1 |
| Deng, Y | 1 |
| Eidenschenk, C | 1 |
| Everett, C | 1 |
| Ganguli, A | 1 |
| Hawkins, J | 1 |
| Johnson, AR | 1 |
| La, H | 1 |
| Norman, M | 1 |
| Salmon, G | 1 |
| Summerhill, S | 1 |
| Ouyang, W | 1 |
| Tang, W | 1 |
| Wong, H | 1 |
| Kim, HJ | 1 |
| Jeong, IK | 1 |
| Hur, KY | 1 |
| Kim, SK | 1 |
| Noh, JH | 1 |
| Chun, SW | 1 |
| Kang, ES | 1 |
| Rhee, EJ | 1 |
| Choi, SH | 1 |
| Vis, DC | 1 |
| Kelly, MM | 1 |
| De Heuvel, E | 1 |
| MacEachern, PR | 1 |
| Yamada, T | 1 |
| Hiraoka, E | 1 |
| Miyazaki, T | 1 |
| Sato, J | 1 |
| Ban, N | 1 |
| Okunuki, Y | 1 |
| Usui, Y | 1 |
| Nakagawa, H | 1 |
| Tajima, K | 1 |
| Matsuda, R | 1 |
| Ueda, S | 1 |
| Hattori, T | 1 |
| Kezuka, T | 1 |
| Goto, H | 1 |
| Ferrari, SM | 1 |
| Antonelli, A | 1 |
| Di Domenicantonio, A | 1 |
| Manfredi, A | 1 |
| Ferri, C | 1 |
| Fallahi, P | 1 |
| Yuan, Z | 3 |
| Liu, Y | 8 |
| Zhang, J | 3 |
| Kishimoto, C | 4 |
| Wang, Y | 2 |
| Ma, A | 3 |
| Liu, Z | 3 |
| Yuan, ZY | 1 |
| Zhang, JJ | 1 |
| Liu, ZQ | 1 |
| Hasegawa, H | 1 |
| Takano, H | 1 |
| Zou, Y | 1 |
| Qin, Y | 1 |
| Hizukuri, K | 1 |
| Odaka, K | 1 |
| Toyozaki, T | 1 |
| Komuro, I | 1 |
1 review available for pioglitazone and Autoimmune Disease
| Article | Year |
|---|---|
Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines.
Topics: Animals; Autoimmune Diseases; Chemokines; Disease Models, Animal; Europe; Humans; Immunity, Cellular | 2014 |
1 trial available for pioglitazone and Autoimmune Disease
| Article | Year |
|---|---|
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, T | 2022 |
9 other studies available for pioglitazone and Autoimmune Disease
| Article | Year |
|---|---|
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Topics: Animals; Autoimmune Diseases; Cell Line; Cells, Cultured; Drug Discovery; HEK293 Cells; Humans; Imid | 2015 |
Reduction in Alveolar Macrophage Size in Refractory Autoimmune Pulmonary Alveolar Proteinosis After Treatment With Pioglitazone.
Topics: Autoimmune Diseases; Bronchoalveolar Lavage Fluid; Fibrosis; Granulocyte-Macrophage Colony-Stimulati | 2020 |
Diabetes as First Manifestation of Autoimmune Pancreatitis.
Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli | 2017 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Female; Flow Cytometry; Humans; Hypoglycemic A | 2013 |
Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis.
Topics: Animals; Autoimmune Diseases; Hypoglycemic Agents; Interleukin-1; Models, Animal; Myocarditis; Piogl | 2003 |
[Peroxisome proliferation-activated receptor-gamma ligands ameliorate autoimmune myocarditis associated with inhibition of T cell immunity].
Topics: Animals; Autoimmune Diseases; Immunosuppressive Agents; Myocarditis; Pioglitazone; Prostaglandin D2; | 2003 |
Peroxisome proliferator-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis associated with inhibition of self-sensitive T cells.
Topics: Animals; Autoimmune Diseases; Cells, Cultured; Dose-Response Relationship, Drug; Ligands; Myocarditi | 2004 |
Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance.
Topics: Animals; Autoimmune Diseases; Body Weight; Cytokines; Disease Models, Animal; Female; Hemodynamics; | 2005 |
Cardioprotective effects of peroxisome proliferator activated receptor gamma activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor kappaB blockade.
Topics: Acute Disease; Animals; Autoimmune Diseases; Cardiotonic Agents; Cytokines; Gene Expression Regulati | 2005 |